Skip to Content

Clopidogrel Teva Generics B.V.

Active Substance: clopidogrel hydrochloride
Common Name: clopidogrel
ATC Code: B01AC04
Marketing Authorisation Holder: Teva Pharma B.V.
Active Substance: clopidogrel hydrochloride
Status: Withdrawn
Authorisation Date: 2010-10-28
Therapeutic Area: Peripheral Vascular Diseases Stroke Acute Coronary Syndrome Myocardial Infarction
Pharmacotherapeutic Group: Antithrombotic Agents

Therapeutic Indication

Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:

  • Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
  • Patients suffering from acute coronary syndrome:
    • Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
    • ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.

For further information please refer to section 5.1.

The marketing authorisation for Clopidogrel Teva Generics B.V. has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide